Serogroup C meningococcal conjugate vaccines, first launched in the UK in 1999, have been used successfully in Australia, Canada and several other European countries. Combination conjugate vaccines, containing more than one meningococcal polysaccharide, have been developed to broaden protection against the disease. A tetravalent meningococcal A, C, Y and W-135 conjugate vaccine was licensed for use in 11-55 year old adolescents and adults in the US in January 2005, and subsequently also in 2-11 year old children in Canada in May 2006. This article discusses the different glycoconjugate meningococcal vaccines which have been developed and the potential for their use to control disease caused by serogroups A, C, Y and W-135 of Neisseria meningitidis.

Original publication

DOI

10.1136/adc.2006.111500

Type

Journal

Arch Dis Child

Publication Date

10/2007

Volume

92

Pages

909 - 915

Keywords

Adolescent, Age Factors, Australia, Canada, Child, Child, Preschool, Female, Humans, Infant, Male, Meningitis, Meningococcal, Meningococcal Infections, Meningococcal Vaccines, United Kingdom